Famotidine Powder, For Suspension
NDC 42571-433
Product Information
Famotidine is a ANDA-approved product labeled by Micro Labs Limited. Famotidine is used to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed. It is supplied as a white powder, for suspension for oral administration. This product entry covers the primary NDC 42571-433 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 42571-433?
What are the uses of this product?
What are Active Ingredients of this product?
- FAMOTIDINE 40 mg/5mL - A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- FAMOTIDINE (UNII: 5QZO15J2Z8)
- FAMOTIDINE (UNII: 5QZO15J2Z8) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)
- POWDERED CELLULOSE (UNII: SMD1X3XO9M)
- SUCROSE (UNII: C151H8M554)
- XANTHAN GUM (UNII: TTV12P4NEE)
- SODIUM BENZOATE (UNII: OJ245FE5EU)
- METHYLPARABEN SODIUM (UNII: CR6K9C2NHK)
- PROPYLPARABEN SODIUM (UNII: 625NNB0G9N)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 310274 - famotidine 40 MG in 5 mL Oral Suspension
- RxCUI: 310274 - famotidine 8 MG/ML Oral Suspension
- RxCUI: 310274 - famotidine 40 MG per 5 ML Oral Suspension
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.